Mk-2461

Mk-2461

SCHEMBL1270764

CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MET

The experimentally established mechanism targets of Mk-2461. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET known ✓ P08581 20/20 0.98
MST1R Q04912 2/20 0.98
AURKA O14965 1/20 0.98
JAK2 O60674 1/20 0.98
ABL1 P00519 1/20 0.98
NTRK1 P04629 1/20 0.98
RET P07949 1/20 0.98
CYP3A4 P08684 1/20 0.98
PDGFRB P09619 1/20 0.98
FGFR1 P11362 1/20 0.98
CYP2C9 P11712 1/20 0.98
NQO2 P16083 1/20 0.98
FLT1 P17948 1/20 0.98
FGFR2 P21802 1/20 0.98
FGFR3 P22607 1/20 0.98
FECH P22830 1/20 0.98
FLT4 P35916 1/20 0.98
KDR P35968 1/20 0.98
FLT3 P36888 1/20 0.98
MAPK9 P45984 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mk-2461 SCHEMBL29356324 0.99 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29529144 0.99 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29394185 0.99 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL93526 0.99 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL2326614 0.99 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL2326906 0.99 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1270766 0.98 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1269865 0.98 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1269863 0.98 MET (0.98) METMST1RAURKAJAK2ABL1
SCHEMBL4316174 0.91 MET (0.84) METMST1RAURKAJAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893081-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2011-02-22 US claimed
US-20090182002-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-07-16 US claimed
US-7893081-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2011-02-22 US disclosed
US-20090182002-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182002-A1 Tyrosine kinase inhibitors JAK1, JAK2, LCK MET 19/4885MST1R 41/4885AURKA 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.